As of 2025-03-19, the Relative Valuation of Arrowhead Pharmaceuticals Inc (ARWR) is (89.03) USD. This relative valuation is based on P/E multiples. With the latest stock price at 15.10 USD, the upside of Arrowhead Pharmaceuticals Inc based on Relative Valuation is -689.8%.
The range of the Relative Valuation is (84.11) - (119.12) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.6x - 27.9x | 16.9x |
| Forward P/E multiples | 16.0x - 23.5x | 18.2x |
| Fair Price | (84.11) - (119.12) | (89.03) |
| Upside | -657.2% - -889.1% | -689.8% |
| Date | P/E |
| 2025-03-18 | -2.98 |
| 2025-03-17 | -3.08 |
| 2025-03-14 | -3.03 |
| 2025-03-13 | -2.97 |
| 2025-03-12 | -3.11 |
| 2025-03-11 | -2.97 |
| 2025-03-10 | -3.00 |
| 2025-03-07 | -3.35 |
| 2025-03-06 | -3.48 |
| 2025-03-05 | -3.42 |
| 2025-03-04 | -3.37 |
| 2025-03-03 | -3.49 |
| 2025-02-28 | -3.73 |
| 2025-02-27 | -3.73 |
| 2025-02-26 | -3.79 |
| 2025-02-25 | -3.85 |
| 2025-02-24 | -3.72 |
| 2025-02-21 | -3.92 |
| 2025-02-20 | -4.13 |
| 2025-02-19 | -4.16 |
| 2025-02-18 | -4.03 |
| 2025-02-14 | -3.93 |
| 2025-02-13 | -3.77 |
| 2025-02-12 | -3.66 |
| 2025-02-11 | -3.72 |
| 2025-02-10 | -3.93 |
| 2025-02-07 | -3.99 |
| 2025-02-06 | -4.04 |
| 2025-02-05 | -4.00 |
| 2025-02-04 | -3.88 |
| 2025-02-03 | -3.69 |
| 2025-01-31 | -3.92 |
| 2025-01-30 | -3.99 |
| 2025-01-29 | -3.93 |
| 2025-01-28 | -3.95 |
| 2025-01-27 | -3.99 |
| 2025-01-24 | -4.09 |
| 2025-01-23 | -4.24 |
| 2025-01-22 | -3.89 |
| 2025-01-21 | -3.90 |
| 2025-01-17 | -3.86 |
| 2025-01-16 | -3.75 |
| 2025-01-15 | -3.73 |
| 2025-01-14 | -3.56 |
| 2025-01-13 | -3.73 |
| 2025-01-10 | -3.64 |
| 2025-01-08 | -3.89 |
| 2025-01-07 | -3.88 |
| 2025-01-06 | -3.84 |
| 2025-01-03 | -3.90 |